AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01786694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cma microdialysis catheter placement
Description: the microdialysis catheters are sold by CMA
Study NCT03760965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03760965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03760965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04754919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transition intervention group
Description: Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
Study NCT04754919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post transition group
Description: The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
Study NCT04234373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb diet
Description: Low Carb diet (max. 130g carbohydrates/d) for 6 months
Study NCT04389619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Microneedling Radiofrequency
Description: In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
Study NCT04389619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Steroid Injection with and without Microneedling
Description: In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
Study NCT00656019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 0, 2000, 4000, and 6000 IU per day orally
Study NCT01716507 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retinal Detachment repair
Description: Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
Study NCT02732886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medifoam®
Description: Foam Dressing
Study NCT01970072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Study NCT01788683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment
Study NCT01788683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study NCT01194674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
Study NCT02095262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reactive auditory training
Study NCT02095262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive auditory training
Study NCT02732886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Betafoam®
Description: Foam dressing including Betadine iodine
Study NCT01079078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT01079078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT01966341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/ Hypnotherapy
Description: The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
Study NCT01966341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Management
Description: Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
Study NCT00665626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: R935788 100 mg tablet, orally, twice-a-day
Study NCT00665626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, twice-a-day
Study NCT01488071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally
Study NCT01488071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agomelatine
Description: encapsulated tablets, daily, orally
Study NCT04071275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
Study NCT04071275 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
Study NCT04071275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
Study NCT04071275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
Study NCT04071275 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
Study NCT02635477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Behavioral: actigraphy device, adaptive step count algorithm
Study NCT02635477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Behavioral: actigraphy device, step count measurement only
Study NCT02966067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Device (Experimental)
Description: Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
Study NCT02966067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-gauge Short Hypodermic Needle
Description: Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
Study NCT01646476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered stent (Bona stent pyloric/duodenal covered) insertion
Description: self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
Study NCT01646476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered stent (Bona stent, pyloric/duodenal) insertion
Description: Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
Study NCT00968669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 30 mg
Description: MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Study NCT00968669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 100 mg
Description: MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Study NCT00968669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 300 mg
Description: MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Study NCT00968669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
Study NCT00319020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
Study NCT01311856 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard Arm (mail/telephone)
Description: Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
Study NCT01311856 — intervention group
Intervention type: BEHAVIORAL
Intervention: Internet Arm
Description: Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
Study NCT02376907 — intervention group
Intervention type: PROCEDURE
Intervention: Biliary drainage
Description: EUS-BD or ERCP
Study NCT01628276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cog Rehab
Description: Cognitive rehab for MS patients
Study NCT03373591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine TAP block
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
Study NCT03373591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine TAP block
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
Study NCT03735550 — intervention group
Intervention type: DEVICE
Intervention: Contact thermographic breast examination device
Description: A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given open labeled placebo PO
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given open labeled placebo PO
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03927885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: Assigned to a waiting list
Study NCT03354676 — intervention group
Intervention type: OTHER
Intervention: MetS+
Description: Data processing from Patient Medical Files
Study NCT03354676 — intervention group
Intervention type: OTHER
Intervention: MetS-
Description: Data processing from Patient Medical Files
Study NCT04102501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
Study NCT04102501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
Study NCT04491500 — intervention group
Intervention type: BEHAVIORAL
Intervention: High attitude environment
Description: The participants will go to 4000m altitude to work for two weeks.
Study NCT03397446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: 50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
Study NCT04277598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APO-2
Description: APO-2: dose adjusted gel for topical administration.
Study NCT01970072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT03015337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New physical education instructions
Study NCT04517409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
Study NCT04517409 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment.
Study NCT02481206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Cardioverter Defibrillator
Description: Wearable Cardioverter Defibrillator
Study NCT02715193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Study NCT02715193 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT02013817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
Study NCT02013817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Every 4 weeks, 6 cycles
Study NCT02013817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Every 4 weeks, 3 cycles
Study NCT01311856 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys and Questionnaires
Description: 9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
Study NCT01984320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
Study NCT00972686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 is an experimental treatment for patients with cancer.
Study NCT01535625 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Momo stent
Description: Patients with PCI
Study NCT03786783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00180843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol + ipratropium bromide nebules
Study NCT00180843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nebulized saline
Study NCT02564601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Training
Description: The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
Study NCT02564601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Cognitive Training
Description: The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
Study NCT01311856 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise and Diet
Description: 15 minutes of strength exercise every other day, >30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
Study NCT03592238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.